Replies to post #85727 on Biotech Values

[genisi]

Typo correction: in the first sentence it should have been 3Q09 US sales of Copaxone not 2Q09.

[genisi]

Before srsmgja jumps: Copaxone took two price hikes of 10% each, in Jan and in Apr 2009.

[genisi]

Record global in-market sales of Copaxone of $2.8 billion in the year ended 2009, up 25% in the fourth quarter and for the full year compared to 2008. Copaxone® continues to be the leading MS therapy in the U.S. and globally.

Teva Reports Record Full Year 2009 And Fourth Quarter Results

http://www.tevapharm.com/pr/2010/pr_905.asp